FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism
The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline...
Karuna Therapeutics
BMS to Acquire Karuna Therapeutics for $14 Billion, Expanding Psychosis Treatment Portfolio
Bristol Myers Squibb (BMS; NYSE: BMY), a leading US pharmaceutical company, has announced its intention...